The World Health Organization has announced that it has cleared the emergency use of China’s Sinovac vaccine, which is still in use in Turkey.
The Strategic Advisory Group of Experts (SAGE), which advises WHO on the use of Kovid-19 vaccines, has also completed its research on Sinovac, adding: “Based on the available evidence, the WHO recommends that this vaccine is administered in two doses. two to four weeks apart, in adults 18 years and over. recommend its use. expression was used.
In the statement made by the WHO, it was stated that an upper age limit has not been determined for the Sinovac vaccine, because according to the available data, it has been proven that the vaccine also offers protection to patients. the elderly.
Thus, Sinovac became the second vaccine produced by China to be approved for immediate use.
With this approval, Sinovac is expected to be included in the international COVAX vaccination program established by the WHO for poor countries’ access to the vaccine.
PREVENTS 100% OF SERIOUS ILLNESS AND HOSPITAL ADMISSIONS
class = “cf”>
In the statement, in which the results of the efficacy of the Sinovac vaccine were also shared, it was noted that 51% of those vaccinated prevented symptomatic illnesses.
In the statement, it was pointed out that severe cases and hospitalizations were prevented in 100 percent of people who studied the Sinovac vaccine.
The organization first announced on December 31 that the Kovid-19 vaccine produced by the Pfizer-BioNTech company, followed by the Oxford-AstraZeneca vaccine, the vaccine produced by the vaccine maker AstraZeneca Indian Serum Institute (SII), Astra ZenecaBio (South Korea), Moderna and Janssen, which authorized the emergency use of the vaccines it was producing.